Liquid Chromatography Tandem Mass Spectrometry

液相色谱串联质谱法

• 批准号: 7595708
• 负责人: CHRISTINA C. WANG
• 金额: $ 48.74万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595708
• 关键词: Arts; Biological Assay; Biomedical Research; Bone Diseases; California; Chemicals; Child; Clinical; Clinical Research; Core Facility; Diagnosis; Disease; Elderly; Endocrine; Equipment; Funding; HIV; Health Sciences; Hormonal; Hormones; Human; Immunoassay; Institutes; Institution; Joints; Kidney; Laboratories; Liquid Chromatography; Liquid substance; Los Angeles; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Medical center; Metabolic; Metabolic Bone Diseases; Metabolism; Methodology; Methods; Monitor; Morbidity - disease rate; Preparation; Protocols documentation; Reproducibility; Research; Research Institute; Research Personnel; Serum; Services; Sister; Technology; Translational Research; Underserved Population; United States National Institutes of Health; Universities; Vitamin Deficiency; Vitamins; Woman; mass spectrometer; men; patient population; programs; public health relevance; small molecule; tandem mass spectrometry

DESCRIPTION (provided by applicant): The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA Biomed) General Clinical Research Center (GCRC) is applying for a Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS) for the GCRC Core Laboratory and the Biomedical Mass Spectrometry Facility. The LC/MS/MS is requested to serve the needs of clinical and translational investigators at Harbor-LA Biomed and our sister institutions in Los Angeles (Cedars Sinai Medical Center (Cedars-Sinai), UCLA-Westwood, and the Charles Drew University of Health and Science (Drew)). The sharing of the services of this equipment is an important part of our preparation for a joint application for a Clinical and Translational Sciences Institute (CTSI) across the four sister institutions. To avoid duplication, increase efficiency and optimize utilization in the laboratory, the program and laboratories directors of the GCRCs at UCLA Westwood, Cedars-Sinai, Harbor-LA Biomed and Drew have agreed to designate the Harbor-UCLA GCRC Core Lab and Biomedical Mass Spectrometry facility as the central Endocrine and Metabolism Core Laboratory for all four CTSI institutions. Currently, the GCRC Core Laboratory provides hormone and vitamin analyses mostly by immunoassays. These methodologies have higher variance, poorer reproducibility and in many instances less accuracy than that obtained from LC/MS/MS. The challenges of clinical assays of small molecules in research include the requirements of high sensitivity and low limit of quantitation (LOQ) into the low fentomolar range. Such sensitivity is necessary in order to be able to accurately diagnose hormonal or vitamin deficiency and to monitor its treatment in men, women and children. Our current investigators include 6 major NIH users with 15 protocols, 9 NIH funded users and 6 other junior and funded investigators. These investigators are engaged in a wide spectrum of research spanning from metabolic bone diseases inflicting children and the elderly, hormonal deficiencies in men and women, hormone and non-hormone dependent cancers, co-morbidities of HIV disease and importantly, understanding mechanisms underlying these diseases. With expansion of validated assay portfolio we anticipate that we can support more than twice the research protocols. This application is strongly supported by all four participating institutions. The strengthening of the Core Facilities providing Mass Spectrometry Technology capability will also significantly enhance our ability to serve not only our institution but our sister institutions at UCLA, Cedars-Sinai, and Drew in Southern California and our diverse and often underserved patient population. PUBLIC HEALTH RELEVANCE: The Harbor-UCLA General Clinical Research Center is requesting the funding of a state of the art, high-throughput liquid chromatography tandem mass spectrometer to measure serum hormones and other metabolic products in human bodily fluids. This will allow the measurement of very small amounts of these hormones and chemicals with very high selectivity, accuracy and precision. The application of this method will support many investigators from LA BioMed, Cedars-Sinai, UCLA-Westwood and Drew University in the diagnosis and monitoring of treatment of many metabolic, endocrine, kidney an bone disease for our underserved population.

描述（由申请人提供）：洛杉矶生物医学研究所 Harbour-UCLA 医疗中心 (LA Biomed) 一般临床研究中心 (GCRC) 正在为 GCRC 核心申请液相色谱串联质谱仪 (LC-MS/MS)实验室和生物医学质谱设施。 LC/MS/MS 旨在满足 Harbor-LA Biomed 以及我们在洛杉矶的姊妹机构（Cedars Sinai 医疗中心 (Cedars-Sinai)、加州大学洛杉矶分校韦斯特伍德分校和查尔斯·德鲁大学）的临床和转化研究人员的需求。健康与科学（德鲁））。共享该设备的服务是我们为四个姊妹机构联合申请临床和转化科学研究所 (CTSI) 做准备的重要组成部分。为了避免重复、提高效率并优化实验室利用率，加州大学洛杉矶分校韦斯特伍德分校、西达斯西奈分校、Harbor-LA Biomed 和 Drew 的 GCRC 项目和实验室主任已同意指定 Harbour-UCLA GCRC 核心实验室和生物医学质谱该设施是所有四个 CTSI 机构的中央内分泌和代谢核心实验室。目前，GCRC核心实验室主要通过免疫分析提供激素和维生素分析。这些方法与 LC/MS/MS 相比具有较高的方差、较差的重现性，并且在许多情况下准确性较低。研究中小分子临床测定的挑战包括高灵敏度和低分摩尔范围的定量限 (LOQ) 要求。为了能够准确诊断男性、女性和儿童的激素或维生素缺乏症并监测其治疗情况，这种敏感性是必要的。我们目前的研究人员包括 6 名 NIH 主要用户（拥有 15 个协议）、9 名 NIH 资助用户和 6 名其他初级和资助研究人员。这些研究人员从事广泛的研究，涵盖儿童和老年人的代谢性骨病、男性和女性的激素缺乏、激素和非激素依赖性癌症、艾滋病毒疾病的共病，以及重要的是了解这些疾病的潜在机制。随着经过验证的检测产品组合的扩展，我们预计可以支持两倍以上的研究方案。本次申请得到了四家参与机构的大力支持。加强提供质谱技术能力的核心设施也将显着增强我们的能力，不仅为我们的机构提供服务，而且为我们在加州大学洛杉矶分校、西达斯西奈分校和南加州德鲁的姊妹机构以及我们多样化且经常服务不足的患者群体提供服务。公共健康相关性：Harbor-UCLA 普通临床研究中心正在请求资助最先进的高通量液相色谱串联质谱仪，以测量人体体液中的血清激素和其他代谢产物。这将能够以非常高的选择性、准确度和精密度测量极少量的激素和化学物质。该方法的应用将支持来自 LA BioMed、Cedars-Sinai、UCLA-Westwood 和德鲁大学的许多研究人员为我们服务不足的人群诊断和监测许多代谢、内分泌、肾脏和骨骼疾病的治疗。